Anova Surgical System – Registry Study

Icon for trial | MEMIC-9352 Anova Surgical System – Registry Study

This study is currently enrolling.

You are invited to take part in a patient registry research study. A patient registry is an organized way to collect observational data from a large group of patients undergoing the same procedure. Observational data means that ...

NCT05353257

Shanghai Henlius Biotech, Inc. / “A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC)”

Icon for trial | HLX10-020-SCLC302 Shanghai Henlius Biotech, Inc. / “A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Pla

This study is currently enrolling.

The purpose of this study is to compare the efficacy of the investigational drug and placebo (an inactive substance) in combination with chemotherapy and concurrent radiotherapy in your disease and collect safety information on ...

NCT05629585

: D926XC00001: Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan with or without Durvalumab Versus Investigator’s Choice of Therapy in Patients with Stage I-III Triple Negative Breast Cancer who have Residual Invasive Disease in Breast and/or Axillary Lymph Nodes Following Neoadjuvant Systemic Therapy and Surgical Resection (TROPION-Breast03)

Icon for trial | D926XC00001 : D926XC00001: Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan with or without Durvalumab Versus Investigator’s Choice of Therapy in Patients with Stage I-III Triple Negative Breast Cancer who have Residual Invasive Disea

This study is currently enrolling.

We are doing this study to learn more about whether an investigational drug called datopotamab deruxtecan (also called Dato-DXd), either alone or in combination with another investigational drug called durvalumab, will work and ...

NCT05450692

AstraZeneca AB / “A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY”

Icon for trial | D533BC00001 AstraZeneca AB / “A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whos

This study is currently enrolling.

We are doing this study to learn more about the effect of Ceralasertib plus Durvalumab on the inhibition of tumor growth, and also to better understand the studied disease and associated

NCT05364073

FURMO-002: A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Activating EGFR or HER2 Mutations, Including Exon 20 Insertion Mutations

Icon for trial | FURMO-002 FURMO-002: A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Activating EGFR or HE

This study is currently enrolling.

The purpose of this study is to learn about how the study drug, furmonertinib, works in patients with NSCLC who have a mutation in the EGFR or HER2 gene and how it may help them. For patients with this type of NSCLC, the study ...

Subscribe to